MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1634/theoncologist.2018-0618

Медицинская библиотека · The oncologist · 2019

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini Alessio, Buti Sebastiano, Santini Daniele, Perrone Fabiana, Giusti Raffaele, Tiseo Marcello, Bersanelli Melissa, Michiara Maria, Grassadonia Antonino, Brocco Davide, Tinari Nicola, De Tursi Michele, Zoratto Federica, Veltri Enzo, Marconcini Riccardo, Malorgio Francesco, Garufi Carlo, Russano Marco, Anesi Cecilia, Zeppola Tea, Filetti Marco, Marchetti Paolo, Botticelli Andrea, Antonini Cappellini Gian Carlo, De Galitiis Federica, Vitale Maria Giuseppa, Sabbatini Roberto, Bracarda Sergio, Berardi Rossana, Rinaldi Silvia, Tudini Marianna, Silva Rosa Rita, Pireddu Annagrazia, Atzori Francesco, Chiari Rita, Ricciuti Biagio, Iacono Daniela, Migliorino Maria Rita, Rossi Antonio, Porzio Giampiero, Cannita Katia, Ciciarelli Valeria, Fargnoli Maria Concetta, Ascierto Paolo Antonio, Ficorella Corrado

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors.

MATERIALS AND

METHODS

Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups.

RESULTS

A total of 751 patients were enrolled; median age was 69 years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male/female ratio was 499/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p = .0005) and active pre-existing AIDs (p = .0162), female sex (p = .0004), and Eastern Cooperative Oncology Group Performance Status <2 (p = .0030) were significantly related to a higher incidence of irAEs of any grade. No significant differences were observed regarding grade 3/4 irAEs and objective response rate among subgroups. Pre-existing AIDs were not significantly related with progression-free survival and overall survival.

CONCLUSION

This study quantifies the increased risk of developing irAEs in patients with pre-existing AIDs who had to be treated with anti-PD-1 immunotherapy. Nevertheless, the incidence of grade 3/4 irAEs is not significantly higher when compared with control population. The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.

IMPLICATIONS FOR PRACTICE: Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors but are frequent in clinical practice. This study quantifies the increased risk of developing immune-related adverse events (irAEs) in patients with pre-existing AIDs who had to be treated with anti-programmed death-1 immunotherapy. Nevertheless, their toxicities are mild and the incidence of grade 3/4 irAEs is not significantly higher compared with those of controls. These results will help clinicians in everyday practice, improving their ability to offer a proper counselling to patients, in order to offer an immunotherapy treatment even to patients with pre-existing autoimmune disease.

Для цитирования: Cortellini Alessio, Buti Sebastiano, Santini Daniele, Perrone Fabiana, Giusti Raffaele, Tiseo Marcello, Bersanelli Melissa, Michiara Maria, Grassadonia Antonino, Brocco Davide, Tinari Nicola, De Tursi Michele, Zoratto Federica, Veltri Enzo, Marconcini Riccardo, Malorgio Francesco, Garufi Carlo, Russano Marco, Anesi Cecilia, Zeppola Tea, Filetti Marco, Marchetti Paolo, Botticelli Andrea, Antonini Cappellini Gian Carlo, De Galitiis Federica, Vitale Maria Giuseppa, Sabbatini Roberto, Bracarda Sergio, Berardi Rossana, Rinaldi Silvia, Tudini Marianna, Silva Rosa Rita, Pireddu Annagrazia, Atzori Francesco, Chiari Rita, Ricciuti Biagio, Iacono Daniela, Migliorino Maria Rita, Rossi Antonio, Porzio Giampiero, Cannita Katia, Ciciarelli Valeria, Fargnoli Maria Concetta, Ascierto Paolo Antonio, Ficorella Corrado. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.. The oncologist. 2019. DOI: 10.1634/theoncologist.2018-0618.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.